Labcorp Expands MRD Testing to Enhance Early Cancer Detection and Monitoring
- Laboratory of America Holdings expands its MRD testing portfolio to enhance early cancer recurrence detection.
- New tests, Labcorp Plasma Detect ID and Genome, target specific cancer stages for improved patient monitoring.
- Labcorp's innovative MRD testing aims to facilitate earlier interventions, improving patient outcomes in cancer treatment.
Laboratory of America Holdings Strengthens Cancer Detection with Advanced MRD Testing
Laboratory of America Holdings (Labcorp) is making significant strides in the field of oncology by expanding its molecular residual disease (MRD) testing portfolio. This expansion includes the introduction of Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome, new and innovative tests designed to enhance the early detection of cancer recurrence. As cancer remains a leading health concern, these developments aim to address the pressing challenges posed by the risk of relapse in patients who have previously undergone treatment for various stages of cancer.
Labcorp Plasma Detect ID is tailored for patients diagnosed with stage I–III breast cancer and stage I–IIIA non-small cell lung cancer, while Labcorp Plasma Detect Genome offers a nationwide whole-genome MRD test specifically for stage III colon cancer. Current statistics reveal that approximately 35% of stage III colon cancer patients and up to 40% of stage I-III breast cancer patients face the risk of recurrence following treatment. The ability of MRD testing to identify circulating tumor DNA (ctDNA) in the bloodstream allows for the detection of recurrences months in advance of traditional imaging methods. Labcorp's tests demonstrate a sensitivity of detection as low as 0.005%, enabling oncologists to develop tailored surveillance strategies that can significantly improve patient care and recovery outcomes.
The importance of ongoing monitoring post-treatment cannot be overstated. Dr. Shakti Ramkissoon, Labcorp's vice president and medical lead for oncology, emphasizes that the ongoing evaluation of patients who have completed treatment is crucial. The expansion of Labcorp’s Plasma Detect portfolio not only signifies a major advancement in the tracking of molecular residual disease but also reinforces Labcorp's commitment to personalized cancer care. By offering non-invasive testing options, Labcorp aims to facilitate earlier interventions, ultimately improving patient outcomes and contributing to the evolving landscape of cancer treatment.
In addition to its new testing offerings, Labcorp continues to participate actively in clinical research, with recent studies focusing on the efficacy of the Plasma Detect tests across various cancer types. This ongoing commitment to innovation and research highlights Labcorp's role as a leader in the laboratory services sector, positioning the company to play a pivotal role in transforming cancer care through advanced molecular diagnostics.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

